EGFR and neoplasm: A trend appealing a shorter OS was found in patients with tumor carrying Myc pathway alterations compared to those without alterations whether an anti-EGFR or VEGF antibody was used as first-line treatment (HR: 5.109; 95% CI: 0.827–31.56; p = 0.05 and HR: 3.076; 95% CI: 0.902–10.49; p = 0.05, respectively; Figure 5E,F).